NCT04260932 is a Phase 1 clinical trial of CD19/CD20 Dual-CAR-T cells in B-cell Lymphoma, sponsored by Hebei Yanda Ludaopei Hospital.

Who is sponsoring NCT04260932?

NCT04260932 is sponsored by Hebei Yanda Ludaopei Hospital.

What drugs are being tested in NCT04260932?

Interventions in NCT04260932: CD19/CD20 Dual-CAR-T cells.

What condition does NCT04260932 study?

NCT04260932 studies B-cell Lymphoma.

Is NCT04260932 still recruiting?

NCT04260932 is currently completed. Last updated 8 March 2022.

Last reviewed 2022-03-08 · How we verify

NCT04260932

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

Completed Phase 1 Last updated 8 March 2022

What this trial tests

Phase 1 trial testing CD19/CD20 Dual-CAR-T cells in B-cell Lymphoma in 12 participants. Completed in 10 September 2021.

Timeline

1 March 2020

Primary endpoint
10 May 2021

10 September 2021

Quick facts

Lead sponsor	Hebei Yanda Ludaopei Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 March 2020
Primary completion	10 May 2021
Estimated completion	10 September 2021
Sites	1 location across China

Drugs / interventions tested

CD19/CD20 Dual-CAR-T cells — full drug profile →

Conditions studied

B-cell Lymphoma — all drugs for B-cell Lymphoma →

Sponsor

Hebei Yanda Ludaopei Hospital

Who can join

Adults 1 to 80, any sex, with B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell lymphoma.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z, Zhang Y, Wang X. · · 2021 · cited 30× · PMID 34256851 · DOI 10.1186/s40364-021-00309-5
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.
Qin H, Zhou Z, Shi R, Mai Y, et al · · 2025 · cited 15× · PMID 40483473 · DOI 10.1186/s13045-025-01701-6
The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
Satapathy BP, Sheoran P, Yadav R, Chettri D, et al · · 2024 · cited 13× · PMID 38799440 · DOI 10.3389/fimmu.2024.1389971
A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.
Atrash S, Moyo TK. · · 2021 · cited 11× · PMID 33814917 · DOI 10.2147/ott.s242018
Multi-targeted immunotherapeutics to treat B cell malignancies.
Gambles MT, Yang J, Kopeček J. · · 2023 · cited 8× · PMID 37121515 · DOI 10.1016/j.jconrel.2023.04.048
CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies.
Faeq MH, Al-Haideri M, Mohammad TAM, Gharebakhshi F, et al · · 2023 · cited 7× · PMID 37083979 · DOI 10.1007/s12032-023-02019-4

Verify or expand the search:

Other trials of CD19/CD20 Dual-CAR-T cells

Trials testing the same drug.

NCT04697290 — CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. · EARLY_PHASE1 · suspended
NCT04260945 — CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients · Phase 1 · completed

Other recruiting trials for B-cell Lymphoma

Currently open trials in the same condition.

NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
NCT06758713 — Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies · Phase 1 · recruiting
NCT06820268 — A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies · Phase 1 · recruiting
NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
NCT06744075 — Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma · NA · active not recruiting

Other Hebei Yanda Ludaopei Hospital trials

Trials by the same sponsor.

NCT05590091 — Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients · NA · unknown
NCT05518357 — LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · completed
NCT04508842 — CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) · Phase 1 · terminated
NCT04260945 — CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients · Phase 1 · completed
NCT04156217 — EBV-TCR-T Cells for EB Virus Infection After HSCT · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04260932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Yanda Ludaopei Hospital
Last refreshed: 8 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04260932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing